HIV-1 Treatment-as-Prevention
暂无分享,去创建一个
H. Xing | Y. Ruan | Y. Shao | Y. Chen | Heng Zhang | Zhen-zhu Tang | Zhiyong Shen | G. Lan | Yi Chen | Q. Zhu | W. Kan | Xiaoyi Yang
[1] H. Xing,et al. HIV, Syphilis, and Behavioral Risk Factors among Female Sex Workers before and after Implementation of Harm Reduction Programs in a High Drug-Using Area of China , 2014, PloS one.
[2] J. Montaner,et al. Antiretroviral Therapy Reduces HIV Transmission in Discordant Couples in Rural Yunnan, China , 2013, PloS one.
[3] Yiming Shao,et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study , 2013, The Lancet.
[4] Ning Wang,et al. Heterosexual transmission of HIV and related risk factors among serodiscordant couples in Henan province, China , 2013, Chinese medical journal.
[5] S. Cole,et al. Decreasing Excess Mortality of HIV-Infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003–2009 , 2013, Journal of acquired immune deficiency syndromes.
[6] S. Vermund,et al. Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China , 2013, AIDS.
[7] W. Liu,et al. Incidence and Associated Factors of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving Antiretroviral Treatment , 2013, PloS one.
[8] H. Xing,et al. Evaluation of Harm Reduction Programs on Seroincidence of HIV, Hepatitis B and C, and Syphilis Among Intravenous Drug Users in Southwest China , 2013, Sexually transmitted diseases.
[9] W. Liu,et al. HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected Patients , 2013, PloS one.
[10] Ning Wang,et al. HIV seroconversion and prevalence rates in heterosexual discordant couples in China: A systematic review and meta-analysis , 2012, AIDS care.
[11] S. Cole,et al. Attrition among Human Immunodeficiency Virus (HIV)- Infected Patients Initiating Antiretroviral Therapy in China, 2003–2010 , 2012, PloS one.
[12] S. Swindells,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2011, Journal of Family Planning and Reproductive Health Care.
[13] Shuntai Zhou,et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. , 2011, The Lancet. Infectious diseases.
[14] Yan Gao,et al. Design and implementation of a China comprehensive AIDS response programme (China CARES), 2003–08 , 2010, International journal of epidemiology.
[15] Ray Y. Chen,et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. , 2010, International journal of epidemiology.
[16] Delpech,et al. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] H. Xing,et al. The Prevalence of Transmitted Antiretroviral Drug Resistance in Treatment-Naive HIV-Infected Individuals in China , 2010, Journal of acquired immune deficiency syndromes.
[18] Ray Y. Chen,et al. Five-Year Outcomes of the China National Free Antiretroviral Treatment Program , 2009, Annals of Internal Medicine.
[19] C. Armon,et al. Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure , 2009, Journal of acquired immune deficiency syndromes.
[20] Jiahong Xu,et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] S. Lai,et al. HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China , 2007, Substance abuse.
[22] M. Kozal,et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.
[23] O. Laeyendecker,et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.
[24] S. Twu,et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. , 2004, The Journal of infectious diseases.
[25] S. Vermund,et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. , 2001, AIDS research and human retroviruses.
[26] S. Lai,et al. Changes in HIV‐1 Incidence in Heroin Users in Guangxi Province, China , 2001, Journal of acquired immune deficiency syndromes.
[27] S. Lai,et al. Changes in HIV-1 incidence in heroin users in Guangxi Province, China. , 2001 .
[28] S. Lai,et al. Adoption of Injection Practices in Heroin Users in Guangxi Province, China , 2000, Journal of psychoactive drugs.
[29] Hiv Survival,et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.
[30] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[31] Jie Chen,et al. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia , 2000, AIDS.
[32] W. Liu,et al. Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. , 1999, Journal of acquired immune deficiency syndromes.
[33] S. Lai,et al. Two subtypes of HIV-1 among injection-drug users in southern China , 1998, The Lancet.